News

Yaz will be launched in all major European markets in autumn 2008. Yaz is said to be the first oral contraceptive on the European market containing the unique

In her new role, Ms Schwalm will have full operating responsibility for leading Eisai Inc., the US commercial operation of Eisai Co., Ltd. She will report to Lonnel

Under the terms of the new collaboration agreement, Spectral will have access to Toray’s distributors in new geographic territories including China, India, Russia and Canada for the sales

Therapy Acceleration Program (TAP) is an innovative program intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers. The TAP funding

The objective of this dose-ranging study is to support dose selection for Phase III, and to inform the ongoing development of a convenient delivery system for this combination

The device has CE certification from the EU allowing European sales for this non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to

The data show that Raptiva therapy had a sustained effect in those patients who responded to the initial 12-week treatment (82%). A 75% improvement in the disease, as

The study will be carried out in cancer patients to test the safety, compatibility and immunological impact of MGN1703. Patients who suffer from the most commonly occurring cancers

Under the terms of the agreement, Merck will be granted access to Spin Signal Technology (SST) utilizing hyperpolarized Xenon 129 gas, a molecular imaging agent that is under